ASLANER, M. Et Al. 2023. Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data. Turkish Journal of Hematology , vol.40, no.2 , 92-100.

ASLANER, M., GEDUK, A., Açar, İ. h., Polat, M. G., SUNU, C., BOLAMAN, Z., ... HACIBEKİROĞLU, T.(2023). Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data. Turkish Journal of Hematology , vol.40, no.2, 92-100.

ASLANER, Müzeyyen Et Al. "Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data," Turkish Journal of Hematology , vol.40, no.2, 92-100, 2023

ASLANER, Müzeyyen Et Al. "Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data." Turkish Journal of Hematology , vol.40, no.2, pp.92-100, 2023

ASLANER, M. Et Al. (2023) . "Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data." Turkish Journal of Hematology , vol.40, no.2, pp.92-100.

@article{article, author={Müzeyyen ASLANER Et Al. }, title={Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data}, journal={Turkish Journal of Hematology}, year=2023, pages={92-100} }